Press Room

CPHI China 2025

Start
Tuesday, June 24, 2025 - 09:00
End
Thursday, June 26, 2025 - 18:00
Location: Shanghai, China
Booth Number: E1C51



Hovione is exhibiting at CPHI China, Asia’s premier pharma event, bringing together suppliers and buyers from the entire pharmaceutical supply chain. Global pharma experts gather in Shanghai to network, inspire innovation and drive change.

If you are facing solubility and bioavailability challenges or just curious about new technologies that address your small molecule and biologics needs, meet the Hovione team at booth # E1C51 and learn more about our leadership in Spray Drying. With the largest number of commercial projects, the best science and engineering, the largest capacity, and the most experienced team, Hovione can take your project from development to market like no one else.

We look forward to seeing you at CPHI China. 

Schedule a meeting today.

 

schedule a meeting

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026